PE20170913A1 - Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol - Google Patents
Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diolInfo
- Publication number
- PE20170913A1 PE20170913A1 PE2017000900A PE2017000900A PE20170913A1 PE 20170913 A1 PE20170913 A1 PE 20170913A1 PE 2017000900 A PE2017000900 A PE 2017000900A PE 2017000900 A PE2017000900 A PE 2017000900A PE 20170913 A1 PE20170913 A1 PE 20170913A1
- Authority
- PE
- Peru
- Prior art keywords
- diol
- octyl
- propane
- phenyl
- ethyl
- Prior art date
Links
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229960000556 fingolimod Drugs 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE: A) UN MODULADOR DEL RECEPTOR ESFINGOSINA-1-FOSFATO (S1P) TAL COMO 2-AMINO-2-[2-(4-OCTIL-FENIL)-ETIL]-PROPANO-1,3-DIOL (FINGOLIMOD) EN UNA CANTIDAD DEL 1.5% O MENOS EN PESO DE LA COMPOSICION; B) UN RELLENO TAL COMO MANITOL; C) UN AGLUTINANTE TAL COMO HIDROXI-PROPIL-CELULOSA; D) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO; Y E) UN ESTABILIZANTE TAL COMO HIDROXI-PROPIL-BETA-CICLODEXTRINA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470747P | 2011-04-01 | 2011-04-01 | |
| US201161545835P | 2011-10-11 | 2011-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170913A1 true PE20170913A1 (es) | 2017-07-12 |
Family
ID=45953284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000900A PE20170913A1 (es) | 2011-04-01 | 2012-03-30 | Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol |
| PE2013002121A PE20140162A1 (es) | 2011-04-01 | 2012-03-30 | Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002121A PE20140162A1 (es) | 2011-04-01 | 2012-03-30 | Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US9592208B2 (es) |
| EP (2) | EP3143990B1 (es) |
| JP (1) | JP6019101B2 (es) |
| KR (1) | KR102027014B1 (es) |
| CN (1) | CN103476400B (es) |
| AR (1) | AR085749A1 (es) |
| AU (1) | AU2012236357B2 (es) |
| BR (1) | BR112013024430B1 (es) |
| CA (1) | CA2831600C (es) |
| CL (1) | CL2013002810A1 (es) |
| CO (1) | CO6771459A2 (es) |
| CY (2) | CY1118423T1 (es) |
| DK (2) | DK2694037T3 (es) |
| EA (2) | EA027721B1 (es) |
| EC (1) | ECSP13012912A (es) |
| ES (2) | ES2610966T3 (es) |
| GT (1) | GT201300227A (es) |
| HR (2) | HRP20170021T1 (es) |
| HU (1) | HUE031286T2 (es) |
| IL (1) | IL228250B (es) |
| JO (1) | JO3177B1 (es) |
| LT (2) | LT3143990T (es) |
| MA (1) | MA34981B1 (es) |
| MX (1) | MX342522B (es) |
| MY (2) | MY175633A (es) |
| PE (2) | PE20170913A1 (es) |
| PH (1) | PH12013501953A1 (es) |
| PL (2) | PL3143990T3 (es) |
| PT (2) | PT2694037T (es) |
| RS (1) | RS59917B1 (es) |
| SG (1) | SG193256A1 (es) |
| SI (2) | SI3143990T1 (es) |
| TW (1) | TWI528958B (es) |
| WO (1) | WO2012135561A1 (es) |
| ZA (1) | ZA201306636B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
| CN103222966A (zh) * | 2013-04-01 | 2013-07-31 | 北京万全德众医药生物技术有限公司 | 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法 |
| CA2920758A1 (en) * | 2013-07-29 | 2015-02-05 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
| US20170231928A1 (en) * | 2014-08-22 | 2017-08-17 | Sunshine Lake Pharma Co., Ltd. | Solid composition of fingolimod and preparation thereof |
| WO2016042493A1 (en) | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| EP3247341A4 (en) * | 2015-01-20 | 2018-12-19 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| EP3419607B1 (en) | 2017-03-29 | 2019-11-20 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
| WO2021158838A1 (en) | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor modulator |
| WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
| WO2025081920A1 (zh) * | 2024-05-13 | 2025-04-24 | 苏州华健瑞达医药技术有限公司 | 一种芬戈莫德口服液体组合物及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5604229A (en) | 1992-10-21 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| SI0812588T1 (en) | 1995-12-28 | 2005-02-28 | Mitsubishi Pharma Corporation | Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| PT990440E (pt) | 1997-02-27 | 2009-02-05 | Novartis Ag | Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido |
| ES2226110T3 (es) | 1997-04-04 | 2005-03-16 | Mitsubishi Pharma Corporation | Compuestos de 2-aminopropano-1,3-diol, su uso medico, e intermedios para sintetizarlos. |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| WO2002018395A1 (en) | 2000-08-31 | 2002-03-07 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| AR043987A1 (es) * | 2003-04-08 | 2005-08-17 | Novartis Ag | Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1 |
| WO2005025553A2 (en) * | 2003-09-12 | 2005-03-24 | Neuronova Ab | Treatment of disorders of nervous systemsystem with fty720 |
| US7888527B2 (en) | 2004-12-06 | 2011-02-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
| GB0502358D0 (en) * | 2005-02-04 | 2005-03-16 | Novartis Ag | Organic compounds |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| BRPI0717570B8 (pt) * | 2006-09-26 | 2021-05-25 | Novartis Ag | composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção |
| MX2009006751A (es) | 2006-12-21 | 2009-06-30 | Abbott Lab | Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato. |
| MY159358A (en) * | 2007-10-12 | 2016-12-30 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| KR20110086142A (ko) | 2008-11-11 | 2011-07-27 | 노파르티스 아게 | 핑골리모드의 염 |
| DK4098256T5 (da) | 2008-12-22 | 2025-07-21 | Novartis Ag | Doseringsregime for en s1p-receptoragonist |
-
2012
- 2012-03-29 JO JOP/2012/0074A patent/JO3177B1/ar active
- 2012-03-29 AR ARP120101074A patent/AR085749A1/es not_active Application Discontinuation
- 2012-03-30 HR HRP20170021TT patent/HRP20170021T1/hr unknown
- 2012-03-30 EA EA201391442A patent/EA027721B1/ru not_active IP Right Cessation
- 2012-03-30 US US14/009,241 patent/US9592208B2/en not_active Expired - Fee Related
- 2012-03-30 ES ES12714163.8T patent/ES2610966T3/es active Active
- 2012-03-30 LT LTEP16176665.4T patent/LT3143990T/lt unknown
- 2012-03-30 LT LTEP12714163.8T patent/LT2694037T/lt unknown
- 2012-03-30 JP JP2014502817A patent/JP6019101B2/ja active Active
- 2012-03-30 MY MYPI2017000050A patent/MY175633A/en unknown
- 2012-03-30 WO PCT/US2012/031340 patent/WO2012135561A1/en not_active Ceased
- 2012-03-30 PL PL16176665T patent/PL3143990T3/pl unknown
- 2012-03-30 MY MYPI2013003216A patent/MY163746A/en unknown
- 2012-03-30 SI SI201231732T patent/SI3143990T1/sl unknown
- 2012-03-30 EA EA201790436A patent/EA035686B1/ru not_active IP Right Cessation
- 2012-03-30 TW TW101111547A patent/TWI528958B/zh active
- 2012-03-30 ES ES16176665T patent/ES2773482T3/es active Active
- 2012-03-30 KR KR1020137025398A patent/KR102027014B1/ko active Active
- 2012-03-30 MA MA36277A patent/MA34981B1/fr unknown
- 2012-03-30 PT PT127141638T patent/PT2694037T/pt unknown
- 2012-03-30 PE PE2017000900A patent/PE20170913A1/es not_active Application Discontinuation
- 2012-03-30 SI SI201230821A patent/SI2694037T1/sl unknown
- 2012-03-30 EP EP16176665.4A patent/EP3143990B1/en active Active
- 2012-03-30 DK DK12714163.8T patent/DK2694037T3/en active
- 2012-03-30 PE PE2013002121A patent/PE20140162A1/es active IP Right Grant
- 2012-03-30 EP EP12714163.8A patent/EP2694037B1/en active Active
- 2012-03-30 CA CA2831600A patent/CA2831600C/en active Active
- 2012-03-30 MX MX2013011415A patent/MX342522B/es active IP Right Grant
- 2012-03-30 PH PH12013501953A patent/PH12013501953A1/en unknown
- 2012-03-30 BR BR112013024430-5A patent/BR112013024430B1/pt active IP Right Grant
- 2012-03-30 PL PL12714163T patent/PL2694037T3/pl unknown
- 2012-03-30 HU HUE12714163A patent/HUE031286T2/hu unknown
- 2012-03-30 DK DK16176665.4T patent/DK3143990T3/da active
- 2012-03-30 CN CN201280017346.1A patent/CN103476400B/zh active Active
- 2012-03-30 AU AU2012236357A patent/AU2012236357B2/en active Active
- 2012-03-30 SG SG2013065867A patent/SG193256A1/en unknown
- 2012-03-30 PT PT161766654T patent/PT3143990T/pt unknown
- 2012-03-30 RS RS20200141A patent/RS59917B1/sr unknown
-
2013
- 2013-09-02 IL IL228250A patent/IL228250B/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06636A patent/ZA201306636B/en unknown
- 2013-09-27 CO CO13230722A patent/CO6771459A2/es unknown
- 2013-09-27 GT GT201300227A patent/GT201300227A/es unknown
- 2013-09-30 CL CL2013002810A patent/CL2013002810A1/es unknown
- 2013-10-01 EC ECSP13012912 patent/ECSP13012912A/es unknown
-
2017
- 2017-01-12 CY CY20171100045T patent/CY1118423T1/el unknown
- 2017-01-30 US US15/418,831 patent/US20170135967A1/en not_active Abandoned
-
2018
- 2018-03-09 US US15/916,371 patent/US20180193291A1/en not_active Abandoned
-
2019
- 2019-04-23 US US16/391,506 patent/US20190247335A1/en not_active Abandoned
-
2020
- 2020-02-14 HR HRP20200249TT patent/HRP20200249T1/hr unknown
- 2020-02-24 CY CY20201100169T patent/CY1122868T1/el unknown
- 2020-05-18 US US16/876,336 patent/US20200276137A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170913A1 (es) | Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol | |
| PE20120337A1 (es) | Producto conteniendo formas de dosificacion oral de fingolimod | |
| CO6270342A2 (es) | Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p) | |
| BR112015014753A2 (pt) | composições, utilização de uma composição, método para o combate dos fungos fitopatogênicos e semente | |
| PE20151890A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MX359413B (es) | Metodos de tratamiento de carcinoma hepatocelular. | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| BR112014018032A2 (pt) | método para produzir uma composição | |
| UY32167A (es) | Nuevos derivados de 2-amidotiadiazol | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| AR091706A1 (es) | Formulaciones de laquinimod sin agentes alcalinizantes | |
| CO6592108A2 (es) | Agonista alfa -2 adrenergico que tiene larga duración en el efecto reductor de la presión intraocular | |
| CO2018003459A2 (es) | Composiciones para el cuidado bucal que comprenden fosfato de zinc y un agente antimicrobiano | |
| CO7170176A2 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo | |
| BR112015000275A2 (pt) | utilização de um extrato de mirta como agente anti-biopelícula face p. acnes | |
| AR085042A1 (es) | Composiciones de cuidado oral con extracto de magnolia | |
| TN2013000425A1 (en) | Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists | |
| BR112014030992A2 (pt) | composições compreendendo calcogenetos e métodos relacionados | |
| PE20142247A1 (es) | Proceso para mejorar la eficiencia de alimentacion y caracteristicas de la canal de los animales | |
| CO7310521A2 (es) | Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo | |
| UY35059A (es) | Método y composición para el tratamiento de ectoparásitos | |
| AR124661A2 (es) | Formulaciones | |
| PE20130381A1 (es) | Composicion farmaceutica solida para administracion bucal de agomelatina | |
| GT201200064A (es) | Composición antiperspirante/desodorante | |
| CO6420413A2 (es) | Composición oral que comprende un sequiterpenoide y un agente antimicrobiano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |